Management

▶ Watch videos on how best NASH and NAFLD can be managed.

Clinical Chemistry in NAFLD Part 2 – Biomarkers and Hepatic Steatosis and NASH

Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH

Discover how key biomarkers like Fatty Liver Index and SteatoTest are transforming NAFLD diagnosis and management. Delve into the disease's pathophysiology, the impact of obesity and insulin resistance, and the advancements in specialized liver tests.
View More ⏩Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH

Clinical Chemistry in NAFLD Part 1 – Interest and Why?

Explore the complexities of NAFLD (Non-Alcoholic Fatty Liver Disease), now also known as MAFLD, and its evolving terminology, diagnostic challenges, and association with cardio-metabolic syndrome. Learn about its progressive nature, the gold standard for diagnosis, and the emerging role of biomarkers. A must-read for healthcare professionals aiming for early diagnosis and effective management.
View More ⏩Clinical Chemistry in NAFLD Part 1 – Interest and Why?
How To Integrate NASH Assessment And Management Into The Care Of Diabetic Patient

How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient

Dr. Laurent Castera (France) discusses how healthcare professionals can integrate non-alcoholic steatohepatitis (NASH) assessment and management into the care of diabetic patients in order to provide a holistic approach for the patient in order for improved patient outcomes.
View More ⏩How to Integrate NASH Assessment and Management Into the Care of Diabetic Patient

NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise

Prof. Stephen Harrison (USA) discusses state of the art management of non-alcoholic steatohepatitis (NASH) in 2022. He focuses on the benefits of lifestyle recommendations, including nutrition and exercise. He shows that weight loss is associated with NASH resolution and fibrosis regression over time following bariatric surgery in patients with severe obesity and NASH.
View More ⏩NASH Management in 2022: benefits of lifestyle recommendations, including nutrition and exercise
Stefan-D.-Anker

Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)

This video presents a comprehensive review of non-alcoholic fatty liver disease (NAFLD) & non-alcoholic steatohepatitis (NASH), delivered by international experts with a multidisciplinary approach: Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom, and Prof. Sven Francque, along with chair, Prof. Stefan Anker. They review the epidemiology of NAFLD / NASH, its increasing prevalence rates, and discuss current best practices to improve patient outcomes.
View More ⏩Getting to the Heart of NAFLD and NASH – The international CVD Perspective (part. 4)

GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3)

In this video, Prof. Sven Francque (Belgium) discusses how vascular mechanisms contribute to non-alcoholic fatty liver disease (NAFLD) and how non-alcoholic steatohepatitis (NASH) contributes to cardiovascular disease (CVD). He also mentions that drugs used to prevent/treat CVD and NAFLD/NASH are safe and those that are used to prevent/treat CVD can have some benefits for NAFLD.
View More ⏩GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 3)
A.G. (Onno) Holleboom Netherlands

Getting to the heart of nafld/nash – the cvd perspective (part 2)

Prof. Onno Holleboom reviews the strong co-occurence of non-alcoholic fatty liver disease (NAFLD) and atherosclerotic cardiovascular (CVD) disease in this video along with joint pathophysiological pathways and its shared drivers. He further looks into NAFLD and its relationships and effects with atherosclerotic CVD and heart failure. For clinicians, he provides an analyses of the management and diagnosis options for advanced NAFLD.  
View More ⏩Getting to the heart of nafld/nash – the cvd perspective (part 2)
Dr. Maarten E Tushuizen

GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 1)

Prof. Maarten Tushuizen provides a comprehensive review on Non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD) and why it is a multisystem disease and further goes on to evaluate their connection to type 2 diabetes mellitus (T2DM) and cardiovascular disease. He also delves into the next steps of managing and diagnosing NASH and NAFLD.
View More ⏩GETTING TO THE HEART OF NAFLD/NASH – THE CVD PERSPECTIVE (PART 1)
pannash Webinar -2

Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

This multidisciplinary discussion on the diabetologist's and hepatologist's perspectives of non-alcoholic fatty liver disease (NAFLD) / non-alcoholic steatohepatitis (NASH), involves international experts, Dr. Maarten Tushuizen, Prof. A.G (Onno) Holleboom and Prof. Christophe Moreno, together with the chair, Professor Manuel Castor Cabezas. The review addresses NAFLD as a multisystem disease, its epidemiology globally and the significance of developing multidisciplinary care paths.
View More ⏩Going beyond the liver in NAFLD/NASH: hepatologist’s / endocrinologist’s perspective

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES